Visceral examination of Bouin’s solution fixed 20-day old rat fetuses treated with <i>U.simensis</i> essential oil: (A) un-sectioned fetus, (B) coronal section of head, V- ventricl... by Bickes Wube (21678222)

DAF-16/FOXO is Required for Locomotory Healthspan and Lifespan Benefits of Genetic Glycolysis Disruption. by Brian Onken (86790)

“…<i>daf-16</i> mutants are documented to have lowered locomotory ability vs. WT later in life [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref091" target="_blank">91</a>, <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.ref092" target="_blank">92</a>]; we note that, although comparison of scores across experiments is not possible due to variation in baseline values, the swimming rate of <i>daf-16(mgDf50)</i> control animals was slightly lower than WT controls on the same day of life (in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008982#pgen.1008982.g001" target="_blank">Fig 1C</a>; mean of 46.17 head thrashes/30 sec. for <i>daf-16</i> vs. 52.17 head thrashes/30 sec. for WT on day 10). …”

Beta-catenin signaling is decreased in intermediate progenitor cells. by Christopher A. Mutch (243132)

“…<p>(<b>A</b>) Cortex from E14.5 Axin2-d2EGFP transgenic mice stained for GFP (green), Tbr2 (red), and DNA (blue). …”

Corticosterone treatment decreases MMP-2 promoter activity. by Eric A. Shikatani (131260)

Decreasing pixel differences caused by worm movement correspond to decreasing locomotive health. by Areta Jushaj (8525655)

Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A by Yasuko Kato (122938)

“…. & reopening group was used as a control (control). The number of PGCs was quantified at P61. …”

Decreased nephrin expression. by Sandra Müller-Krebs (485766)

HIV and neoplasms: What do we know so far? by Thais Faria de Souza (16401420)

Genes with decreased expression in TGFβ-induced EMT. by Kevin A. Maupin (190060)

Substance P decreases PRL immunoreactivity in human epidermis. by Ewan A. Langan (405804)

“…<p>Epidermal PRL IR (black arrows) was examined in full-thickness human skin organ culture. (A) PRL IR in the control group was significantly greater than that in (B) Substance P treated skin. …”

Data_Sheet_5_Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neu... by Yize Li (471459)

“…In conclusion, this study revealed that artesunate alleviates paclitaxel-induced hyperalgesia and spontaneous pain by decreasing DRG mGluR5 expression and neuroinflammation in the mouse model of PINP.…”

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

Subjects:

Mean cold pressor threshold overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

Subjects:

Mean in cold pressor tolerance overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean change in pain severity and interference from baseline to 8 weeks. by Judith I. Tsui (5983160)

Subjects:

Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Subjects:

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects: